3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?
3-Deazaguanine (3-DG) is a new purine antagonist that is active against slow- and rapid-growing solid experimental tumors, especially those that are models for human breast carcinomas. These tumors include mammary adenocarcinomas 13762, R3230AC, and C3H/16C. 3-DG also showed positive activity against leukemias L1210 and L1210/araC, adenocarcinoma 755, and EMT-6 mammary adenocarcinoma. On the basis of its activity against these tumors, 3-DG is to undergo clinical trials.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000963:Antimetabolites / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002460:Cell Line; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D051381:Rats
D000963:Antimetabolites; D006147:Guanine; C010567:3-deazaguanine